BCM
IPXL

Bridgeway Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Bridgeway Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-22,400
Closed -$563K – 1490
2013
Q4 		$563K Buy
+22,400
New +$500K 0.02% 989

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bridgeway Capital Management's IPXL Position: Q1 2014 in Review

Bridgeway Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q1 2014, closing a stake of 22,400 shares — an estimated $563K sold.

Bridgeway Capital Management first reported a position in IPXL in Q4 2013 and held it in 1 quarter. The position peaked at $563K in Q4 2013. 181 funds tracked by Wall St. Rank hold IPXL as of Q1 2014.

  • Bridgeway Capital Management reported no remaining Impax Laboratories, Inc. position as of Q1 2014 after selling out during the quarter.
  • Bridgeway Capital Management sold 22,400 Impax Laboratories, Inc. shares in Q1 2014, an estimated $563K.
  • Bridgeway Capital Management first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 1 quarter.
  • Bridgeway Capital Management's Impax Laboratories, Inc. position peaked at $563K in Q4 2013.
  • 181 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2014.

Based on Bridgeway Capital Management's 13F filing for Q1 2014, filed 15 May 2014.